Biomarin Pharmaceutical INC Form 4 insider transactions

BioMarin Pharmaceutical Inc. director Athena Countouriotis was granted 7,490 restricted stock units as part of equity compensation.

Director Timothy P. Walbert acquired 7,490 restricted stock units in BioMarin Pharmaceutical Inc. as part of a standard equity grant.

BioMarin Pharmaceutical Inc. director Maykin Ho was granted 7,490 restricted stock units as part of an equity compensation arrangement.

Director Robert J. Hombach was granted 7,490 restricted stock units by BioMarin Pharmaceutical Inc. on June 2, 2026.

Director Mark J. Enyedy was granted 7,490 restricted stock units by BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. director Willard H. Dere was granted 7,490 restricted stock units as part of equity compensation.

Director Ian T. Clark acquired 7,490 restricted stock units in BioMarin Pharmaceutical Inc. as part of a standard equity grant.

BioMarin Pharmaceutical Inc. director Barbara W. Bodem was granted 7,490 restricted stock units as part of equity compensation.

Director Elizabeth M. Anderson acquired 7,490 restricted stock units in BioMarin Pharmaceutical Inc. on June 2, 2026.

BioMarin Pharmaceutical Inc. EVP and Chief Commercial Officer Cristin Hubbard disposed of 2,318 shares of common stock to cover tax obligations.

Biomarin Pharmaceutical Inc. executive Gregory R. Friberg reported a sale of 3,281 shares of common stock on May 7, 2026.

BioMarin Pharmaceutical's EVP, Chief Legal Officer, George Eric Davis, reported a sale of 1,273 common shares for tax purposes.

BioMarin Pharmaceutical's EVP, Chief Technical Officer, Charles Greg Guyer, filed a Form 4 detailing a future disposition of 1,693 shares of common stock on March 17, 2026, to cover tax liabilities under a 10b5-1 plan.

BioMarin Pharmaceutical Inc.'s EVP and CFO, Brian Mueller, reported a scheduled disposition of 2,117 shares of common stock for tax liabilities at $56.05 per share.

BioMarin Pharmaceutical Inc.'s CEO, Alexander Hardy, reported a disposition of 4,252 common shares to cover tax liabilities related to a vesting event.

BioMarin Pharmaceutical's EVP and Chief Commercial Officer, Cristin Hubbard, acquired new restricted stock units and stock options, while also disposing of shares for tax withholding.

BioMarin Pharmaceutical's EVP, Chief R&D Officer, Gregory R. Friberg, reported the grant of restricted stock units and stock options, alongside a sale of common stock for tax withholding purposes.

BioMarin Pharmaceutical's EVP and Chief Technical Officer, Charles Greg Guyer, reported the acquisition of restricted stock units and stock options, alongside a disposition of common stock for tax purposes.

BioMarin Pharmaceutical's EVP, Chief Legal Officer, George Eric Davis, reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax purposes.

BioMarin Pharmaceutical Inc.'s EVP and CFO, Brian Mueller, reported the acquisition of restricted stock units and stock options, alongside a disposition for tax purposes.

BioMarin Pharmaceutical CEO Alexander Hardy reported recent transactions involving company common stock and stock options, including the acquisition of restricted stock units and an option grant.

BioMarin Pharmaceutical Inc.'s EVP, Chief Technical Officer, Charles Greg Guyer, sold 16,486 shares of common stock for approximately $60.46 per share.

BioMarin Pharmaceutical Inc.'s EVP, Chief Technical Officer Charles Greg Guyer, earned 15,222 Restricted Stock Units based on 2023-2025 performance metrics.

BioMarin Pharmaceutical's EVP, Chief R&D Officer, Gregory R. Friberg, sold 6,326 shares of common stock for approximately $60.38 per share.

BioMarin Pharmaceutical's EVP, Chief Legal Officer, George Eric Davis, reported the sale of 26,061 common shares and the earning of 15,224 performance-based Restricted Stock Units.

BioMarin Pharmaceutical Inc.'s EVP and CFO, Brian Mueller, earned 16,482 performance-based Restricted Stock Units tied to 2023-2025 company metrics.

BioMarin Pharmaceutical's VP, Chief Accounting Officer, Rashmi Virendra Ramchandani, received grants of restricted stock units and stock options.

BioMarin Pharmaceutical CEO Alexander Hardy reported recent stock acquisitions through an ESPP and subsequent dispositions, adjusting his direct beneficial ownership.

BioMarin Pharmaceutical's EVP and Chief R&D Officer, Gregory R. Friberg, disposed of 3,304 shares of common stock for tax purposes.

BioMarin Pharmaceutical Inc. Director Ian T. Clark was granted 7,000 restricted stock units (RSUs) on August 1, 2025, as reported in a recent SEC Form 4 filing.